Deflatop

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Deflatop

Property Description
Active ingredient Deflazacort
Form Oral Tablet, Oral Suspension
Pharmacological class Synthetic Glucocorticoid
General Purpose Systemic anti-inflammatory and immune modulation
Origin Synthetic Compound

What is the General Classification of Deflatop?

Deflatop is the brand name for a prescription medicine containing the active substance Deflazacort, which is pharmacologically categorized as a synthetic glucocorticoid. This medication belongs to the broader class of systemic corticosteroids, distinguished because its therapeutic activity affects the entire body rather than being restricted to a local site. Deflazacort is structurally differentiated from older compounds like prednisolone; it is a derivative described as having a higher therapeutic index. Deflazacort is recognized for its potent immunosuppressive action. This means the drug helps to control the body's overactive or abnormal immune responses, a necessary function for addressing conditions like systemic rheumatoid disorders. Deflazacort functions as a prodrug, requiring conversion within the body into the active metabolite, 21-desacetyl deflazacort, to exert its primary effects.

Deflatop Composition, Origin, and Form

The medicine is supplied as a single active ingredient product, consisting solely of Deflazacort. This compound is entirely synthetic in origin, developed in a laboratory rather than being a naturally occurring substance, a chemical fact that distinguishes it from naturally derived hormones. Deflatop is primarily administered via the oral route, with the product available in two distinct oral dosage forms: a tablet and an oral suspension. The suspension form is often preferred for pediatric patients or those with difficulty swallowing tablets. This ensures the medicine is absorbed and circulated throughout the body to achieve its generalized physiological effects.

What is the General Purpose of This Type of Medicine?

The general purpose of Deflatop is to utilize its powerful anti-inflammatory capabilities and associated immunosuppressive properties to achieve broad therapeutic control. This class of medicine is generally intended to help manage conditions characterized by widespread and excessive tissue inflammation or an inappropriately heightened immune response. By fundamentally modulating these underlying biological processes, the medication aids in stabilizing the systemic environment in various chronic disorders.

What side effects are possible with Deflatop?

Possible Side Effects and Safety Information

The safety profile of Deflatop (Deflazacort) is officially documented by regulatory authorities, with adverse reactions categorized by frequency and the physiological systems affected. The most common adverse reactions, reported in ge 10% of patients in clinical studies, are primarily related to metabolic and infectious effects.

Officially Documented Adverse Reactions

The most frequently reported effects include Cushingoid appearance, increased weight, increased appetite, central obesity, and various upper respiratory tract infections such as nasopharyngitis and cough. Other documented effects linked to systemic exposure are hirsutism and pollakiuria (frequent urination).

Safety Characteristics by System-Organ Class

Adverse effects are documented across several body systems:

  • Endocrine Function: Prolonged use is associated with the risk of Cushing's syndrome and suppression of the hypothalamic-pituitary-adrenal (HPA) axis, which may lead to acute adrenal insufficiency upon chronic therapy withdrawal.
  • Immune System: As a systemic corticosteroid, Deflazacort causes immunosuppression, raising the risk of acquiring severe, sometimes fatal, infections (viral, bacterial, fungal).
  • Musculoskeletal: Long-term exposure increases the risk of osteoporosis and associated fractures.
  • Ophthalmic: The label documents potential risks of cataract formation and glaucoma.

Serious Reactions and Safety Constraints

Serious adverse reactions explicitly noted in regulatory documents include gastrointestinal perforation, thromboembolic events, and severe dermatological reactions like Toxic Epidermal Necrolysis. Safety constraints require that the medicine should not be used in individuals with a known systemic fungal infection or known hypersensitivity to the drug. For pediatric patients, long-term treatment may potentially slow growth and development, which is a key consideration documented in the official labeling.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation addressing an overdose of Deflazacort (Deflatop) focuses on the potential for systemic consequences inherent to the glucocorticoid class. Acute overdose may not present with a unique set of symptoms but is officially linked to the occurrence of minor changes in body fluids and electrolytes and the potential for changes in heart rhythm.

When severe manifestations occur, regulators mandate that immediate medical help be sought without delay. Urgent action, including calling emergency services, is required if the affected individual is unresponsive, has collapsed, is experiencing a seizure, or has trouble breathing. Contacting a poison control center is also a specified immediate action for obtaining necessary guidance. Any medical provider managing the case will require the full details of the product taken.

No specific antidote is known for Deflazacort overdose. Therefore, the management procedures outlined in official prescribing information are primarily supportive. Medical procedures involve providing symptomatic and supportive treatment and require continuous observation. This often includes monitoring vital signs (such as blood pressure and heart rate) and performing an ECG (electrocardiogram) to assess cardiac function during hospital observation.

Therapeutic Uses of Deflatop

What Deflatop Treats: Main Uses and Benefits

The therapeutic application of Deflatop (Deflazacort) is used across therapeutic domains requiring systemic management of inflammation and immune responses. It is primarily used to address conditions presenting with significant, widespread, or progressive symptomatic patterns. The medication belongs to the corticosteroid class, which is commonly used to help with inflammation and manage the immune system's activity.

Supporting Function and Symptom Management

For pediatric patients with Duchenne Muscular Dystrophy (DMD), its central benefit plays a role in managing the functional progression, where it may help with slowing the rate of progressive muscle degeneration and weakness. This supports maintaining muscle strength and function and assists with managing symptoms of functional decline.

The medicine is commonly used to help with conditions such as DMD, various autoimmune and rheumatic disorders (like Systemic Lupus Erythematosus and Rheumatoid Arthritis), and severe inflammatory states like Severe Asthma and Nephrotic Syndrome. In conditions characterized by periods of heightened symptoms, the medication provides support that helps ease the overall symptom burden and contributes to easing distress from systemic inflammation, pain, swelling, and stiffness.


Quick Fact: Relief for Systemic Discomfort

Deflatop is relevant when supportive symptom management is appropriate, particularly in clinical settings involving symptoms that create noticeable functional strain.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Deflatop

This section describes the official eligibility and non-eligibility information for Deflatop (deflazacort), strictly based on governmental regulatory sources.


Contraindicated Populations

The use of this medicine is contraindicated (prohibited) in patients who have a known hypersensitivity or allergic reaction to deflazacort or any of its inactive ingredients. It is also generally prohibited for patients with certain active infections, including systemic fungal infections, or who are concurrently receiving live or live-attenuated vaccines.


Use Restrictions and Special Considerations

Age: Official labeling indicates use is established for patients 2 years of age and older. Safety and efficacy have not been established for patients under 2 years of age. Special monitoring for growth and development is recommended in the pediatric population.

Condition-Specific Rules:

  • Hepatic Impairment: No dose adjustment is typically required for mild to moderate liver impairment.
  • Infections: Caution is advised, and the risk is increased for patients with a history of or current infections, including tuberculosis, herpes, or fungal infections.
  • Other Conditions: Close monitoring is necessary for patients with pre-existing conditions like diabetes, glaucoma, hypertension, heart problems, peptic ulcer, or osteoporosis, as use may exacerbate these conditions.

Pregnancy and Lactation:

  • Pregnancy: Use is generally restricted and should only occur if the potential benefit justifies the potential risk to the fetus, as adequate studies in pregnant women are lacking.
  • Lactation: Use is generally not recommended, as the medicine may be excreted in breast milk and could potentially affect a nursing infant.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Deflatop's official interaction profile is primarily governed by its metabolism through the CYP3A4 enzyme system. Concomitant use with strong or moderate CYP3A4 inhibitors (e.g., clarithromycin, itraconazole) is documented to increase the drug’s concentration in the body, requiring adjustment by a healthcare provider. Conversely, CYP3A4 inducers (e.g., rifampin, phenytoin) may decrease Deflatop's effectiveness and are typically advised against.

Pharmacodynamic and Substance Interactions

Interactions not related to metabolism include those with a potential for additive effects. For instance, co-administration with potassium-depleting diuretics may enhance the risk of hypokalemia. Taking the drug with NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) carries a documented increased risk of gastrointestinal ulcers and bleeding. Patients using antidiabetic agents may require monitoring and adjustment of their diabetes medication due to the steroid's documented effect on glucose levels.

Restrictions and Special Notes

Official labeling advises against the use of live or live attenuated vaccines due to the immunosuppressive nature of the drug. Additionally, non-medicinal substances like grapefruit juice are documented to increase Deflatop levels and should be avoided.

Mechanism of Action

How Deflatop Works: Mechanism of Action

Deflatop's active component functions as an agonist of the intracellular Glucocorticoid Receptor (GR), a protein present in the cytoplasm of most cells. Upon binding, the activated drug-receptor complex translocates into the cell nucleus. This complex then modulates the transcription of specific genes, a process that involves both increasing (transactivation) and decreasing (transrepression) the expression of various cellular proteins.

This transcriptional control initiates the suppression of key signaling pathways, notably the NF-kappaB cascade, which is central to regulating the cellular production of pro-inflammatory mediators. The mechanism subsequently reduces the synthesis and release of substances like prostaglandins and leukotrienes.

At the systemic level, this action leads to a decrease in capillary permeability and an alteration in the proliferation and activity of immune cells such as lymphocytes and macrophages. These molecular and cellular changes result in a broad physiological modulation of defense responses and a change in fluid dynamics across various tissues.

Dosage and Administration Information

How to Use Deflatop (Deflazacort)

Deflatop administration is structured around established, weight-based protocols designed for precise systemic delivery. The medication is an oral preparation available in two forms: tablets and an oral suspension. Tablets come in several strengths (6 mg, 18 mg, 30 mg, 36 mg) and the suspension is 22.75 mg/ mL.

Official Dosing and Frequency

Administration follows a once-daily schedule. For the primary approved indication of Duchenne Muscular Dystrophy (DMD), the standard regimen is approximately 0.9 mg/ kg of body weight per day. The dose must be carefully calculated and rounded up to the nearest available strength combination for tablets or to the nearest 0.1 mL for the suspension. For other corticosteroid-responsive conditions, initial higher dosing may be followed by lower, long-term maintenance ranges (e.g., 3 mg to 18 mg/ day).

Administration Requirements

The medicine may be taken with or without food. Tablets may be swallowed whole or crushed and mixed with applesauce for immediate intake. The oral suspension must be shaken well and immediately mixed into 3 to 4 ounces of milk or juice prior to administration. It is a specific procedural constraint that the medicine must not be administered with grapefruit or grapefruit juice.

Procedural Discontinuation

If the medicine is taken for more than a few days, the official protocol mandates that the dose must be decreased gradually upon cessation of use. No dose adjustment is required for patients with mild or moderate renal or hepatic impairment, simplifying the use protocol for those specific populations. If a dose is missed, the protocol is to take it upon remembering, unless it is close to the next scheduled dose, in which case the missed dose should be skipped; two doses should not be taken simultaneously.

Recent Clinical Evidence

Evidence for Use in Duchenne Muscular Dystrophy (DMD)

The clinical research for Deflatop in Duchenne Muscular Dystrophy (DMD) has primarily relied upon randomized controlled trials (RCTs). These studies included ambulatory male children and adolescents who were evaluated in a research context exploring short-term symptom changes. Researchers monitored outcomes related to physical discomfort and outcomes reflecting daily functioning by examining changes in muscle strength and the time required to perform functional tasks. Core research data was observed in trials with short-term follow-up (e.g., 12 weeks), with extension studies exploring functional status over intermediate-term periods, typically lasting up to one year.

Evidence for Corticosteroid-Responsive Inflammatory Conditions

Deflatop was studied for use in a broad group of conditions characterized by fluctuating manifestations that require systemic control of inflammation. The evidence base includes systematic reviews and small-scale randomized controlled trials exploring its use in conditions such as Nephrotic Syndrome and various autoimmune disorders. Research examined outcomes linked to inflammatory states and metrics related to the achievement of disease remission. However, the evidence quality varies across studies for these indications. For many individual diseases within this category, the research base consists of a small number of controlled trials, meaning the overall documented clinical experience is limited.

Long-Term Studies and Durability of Research

The available scientific literature includes long-term observational reports that describe the sustained course of the condition. Despite this, follow-up durations were limited in many core efficacy trials. As a result, there is limited information for long-term outcomes when evaluating sustained measurements across all indications.

Evidence in Specific Patient Groups

Primary evidence focused on a specific cohort of ambulatory children, meaning data for certain groups remain insufficient. For instance, evidence is limited for very young children (under five years of age). For inflammatory conditions, the sample sizes were modest in some studies, and the results apply only to the populations studied.

What Research Gaps and Uncertainties Remain

Scientific reviews have identified several areas where certainty remains low or where more research is needed to fully characterize the medicine’s profile. The available research indicates that long-term effects are not fully established regarding changes in life expectancy associated with treatment. Furthermore, comparative evidence is lacking in some contexts, and research is ongoing to address these uncertainties.

Frequently Asked Questions (FAQ)

Common questions about Deflatop (FAQ)

Q: Is Deflatop used for pain relief?

According to official product information, Deflatop is a synthetic glucocorticoid. Its primary role is to act as a powerful anti-inflammatory and immunosuppressive agent to help manage certain chronic conditions. It is not specifically classified in regulatory documents as an analgesic, or pain reliever.

Q: How long does the effect of a single Deflatop dose last?

Regulatory documents state that the active substance in Deflatop, called 21-desacetyl deflazacort, has a short half-life of about 1.5 to 2 hours. This measurement describes the time it takes for half of the drug to be eliminated from the body.

Q: What is the difference between Deflatop and other similar-sounding medicines?

Deflatop contains the active substance Deflazacort, which is categorized as a synthetic glucocorticoid. Official classification documents note that Deflazacort is structurally differentiated from some older compounds in the same class, such as prednisolone.

Q: Does Deflatop affect sleep patterns?

Safety documents from regulatory sources indicate that insomnia, or difficulty sleeping, is among the reported, though uncommon, adverse reactions associated with Deflatop. If any side effect becomes persistent or concerning, the official guidance is to consult a healthcare professional.

Q: Is it normal to feel a little dizzy after starting Deflatop?

Dizziness is not listed in the most frequent side effects reported in clinical studies. However, official safety documentation notes that dizziness has been reported as a post-marketing or rare adverse event in some individuals.

Q: Can Deflatop cause changes in mood or anxiety levels?

Regulatory safety documentation includes potential psychiatric adverse reactions. These effects can include changes in mood, increased irritability, or anxiety.

Q: Is Deflatop safe for older adults to use?

Official labeling does not define specific restrictions or dosage adjustments solely for the general geriatric population (older adults). However, caution and close monitoring are generally necessary because conditions common in older age, such as heart problems or high blood pressure, may require special consideration.

Q: Is Deflatop habit-forming or addictive?

According to regulatory classifications, Deflatop is not categorized as a controlled substance. Official documents regarding drug abuse potential do not list this medication as habit-forming or addictive.

Q: Can I take Deflatop with herbal supplements?

Regulatory documents warn against combining Deflatop with substances that interfere with the CYP3A4 enzyme system, which processes the drug in the body. Certain herbal supplements may interact with this system and pose a documented risk. It is recommended that a healthcare provider review all supplements a patient may be taking.

Q: What should I do if a side effect seems mild but bothersome?

The official procedural guidance is that a healthcare professional or pharmacist should be consulted if any side effect, even one that seems mild, persists or becomes bothersome. This ensures that any change in health is properly evaluated.

Q: Can Deflatop affect my ability to drive or operate machinery?

Caution is generally advised in the official safety information regarding driving or operating machinery. This is because the medication may rarely cause visual disturbances, vertigo, or dizziness, which could affect concentration and coordination.

Q: What are the ingredients in Deflatop besides the main active compound?

The official labeling lists the active ingredient, Deflazacort, as well as a list of inactive ingredients, or excipients. These inactive ingredients are substances like fillers and binders that are required to make up the tablet or suspension form of the medicine.

Q: What is the purpose of the filler ingredients in Deflatop tablets?

The inactive ingredients, sometimes called fillers or excipients, have specific pharmaceutical purposes. They are included in the tablet or suspension formulation to ensure the medicine has the correct structure, physical stability, and proper characteristics for the body to absorb it effectively.

Q: What is the official safety classification of Deflatop?

In its regulated markets, Deflatop is legally classified as a medicine subject to medical prescription. This categorization means that the medication can only be legally dispensed with authorization from a licensed healthcare provider.

Q: Can I take Deflatop with allergy medications?

Official labeling advises that a healthcare provider should review all medications a patient is taking due to the risk of systemic interactions. While common allergy medications (antihistamines) are not specifically listed as prohibited, a comprehensive review of all concurrent medications is required to manage interaction risks.

Q: Are there specific symptoms that Deflatop is NOT intended to treat?

Regulatory documents focus on the specific conditions for which Deflatop has established efficacy, such as Duchenne Muscular Dystrophy (DMD) and various corticosteroid-responsive inflammatory conditions. Conditions that fall outside of these formally established, labeled uses are not the defined purpose of the drug.

Q: Is it common for Deflatop to cause stomach upset?

General 'stomach upset' is not listed among the most common adverse reactions reported in clinical trials. However, the official label does document potential gastrointestinal adverse effects, including risks of ulceration and bleeding, which are particularly enhanced when the drug is taken alongside NSAIDs.

Q: Are there any specific laboratory tests that need to be monitored while on Deflatop?

Official safety sections require that certain health metrics be monitored during long-term use of Deflatop. These typically include monitoring blood glucose levels, blood pressure, and regular ophthalmic (eye) examinations.

Q: If I switch to Deflatop from another medicine, what should I be aware of?

Official documents advise that caution is necessary when a patient transitions from another corticosteroid to Deflatop. The risk of the underlying disease getting worse or experiencing withdrawal symptoms from the previous medicine are key considerations.

Q: Can Deflatop affect birth control pills?

Regulatory information indicates that Deflatop's metabolism may affect the processing of other hormonal substances in the body. While the label does not explicitly rule out an interaction with oral contraceptives, Reviewing the use of oral contraceptives with a healthcare provider is generally recommended.

Q: Does Deflatop cause fatigue?

Fatigue is not listed as a common adverse reaction in the primary safety profile. However, official safety documents describing the drug's effects on the body's metabolic and endocrine systems (like the HPA axis) note changes that may be associated with general weakness or tiredness.

Q: Can Deflatop be taken with common over-the-counter pain relievers?

Regulatory interaction warnings explicitly advise against combining Deflatop with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Taking these together carries a documented increased risk of gastrointestinal ulcers and bleeding.

Q: Why is Deflatop sometimes taken in the morning?

Glucocorticoids like Deflatop are often administered once daily in the morning. This schedule is generally intended to align with the body’s natural circadian rhythm of cortisol release.

Q: Why do doctors recommend tapering off Deflatop instead of stopping suddenly?

Official labeling requires that the medicine be decreased gradually after chronic use. Rapid discontinuation may lead to acute adrenal insufficiency, a serious condition caused by the suppression of the body's natural hormone production (the HPA axis).

Q: How do I know if Deflatop is working for me?

Clinical research used to document the drug's efficacy measured improvements in outcomes like physical function, muscle strength, and reduction of inflammatory symptoms. These documented areas of change are generally what patients and providers look for as indicators of the drug's effects.

Q: Does Deflatop interact with common heart medications?

The official label specifically warns of potential interactions with potassium-depleting diuretics, a type of heart medication. It also states that blood pressure should be monitored closely in patients with pre-existing hypertension (high blood pressure).

Q: How does the drug Deflatop get eliminated from the body?

After the medicine is processed (metabolized) in the liver, official documents state that the majority of the active substance is eliminated from the body. This elimination occurs primarily through the feces and secondarily through the urine.

Q: Is Deflatop available without a prescription in some countries?

In all regulated markets covered by the official documentation, Deflatop is legally categorized as a medicine subject to medical prescription. This classification means it cannot be obtained without a prescription.

Q: What happens if I accidentally take two Deflatop doses close together?

Official procedural guidance advises against taking two doses simultaneously, even when managing a missed dose. Accidental overdose may potentially lead to heightened systemic corticosteroid effects, which may require supportive care.

How should Deflatop be stored and disposed of?

How to Store and Dispose of Deflatop?

The storage and disposal of Deflatop (Deflazacort) must adhere strictly to the conditions specified in official regulatory labeling to ensure product stability and safety.

Storage Requirements

Dosage Form Mandatory Conditions Handling Constraint
Oral Tablet & Suspension Controlled room temperature (20 C to 25 C), away from light and moisture. Do not freeze.

The medication must be kept in the container it came in, with the cap tightly closed after each use. The oral suspension bottle must be stored upright. Crucially, the oral suspension has a limited in-use shelf-life: discard any unused liquid remaining after 1 month of first opening the bottle.

Disposal and Safety

All Deflatop products must be stored out of the sight and reach of children and pets. Unused or expired medicine should be disposed of according to the advice of a healthcare professional. Disposal must be managed to avoid discharge into sewer systems or the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Deflatop found in:

A-Z Index: